SG11202111232RA - Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione - Google Patents
Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneInfo
- Publication number
- SG11202111232RA SG11202111232RA SG11202111232RA SG11202111232RA SG11202111232RA SG 11202111232R A SG11202111232R A SG 11202111232RA SG 11202111232R A SG11202111232R A SG 11202111232RA SG 11202111232R A SG11202111232R A SG 11202111232RA SG 11202111232R A SG11202111232R A SG 11202111232RA
- Authority
- SG
- Singapore
- Prior art keywords
- morpholinoazetidin
- dioxopiperidin
- isoindoline
- dione
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962833432P | 2019-04-12 | 2019-04-12 | |
PCT/US2020/027358 WO2020210418A1 (en) | 2019-04-12 | 2020-04-09 | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111232RA true SG11202111232RA (en) | 2021-11-29 |
Family
ID=70465546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111232RA SG11202111232RA (en) | 2019-04-12 | 2020-04-09 | Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
Country Status (16)
Country | Link |
---|---|
US (2) | US11390617B2 (es) |
EP (1) | EP3952880A1 (es) |
JP (1) | JP2022527398A (es) |
KR (1) | KR20210151895A (es) |
CN (1) | CN114144182B (es) |
AR (1) | AR119715A1 (es) |
AU (1) | AU2020270917A1 (es) |
BR (1) | BR112021020372A2 (es) |
CA (1) | CA3132538A1 (es) |
CL (1) | CL2021002651A1 (es) |
IL (1) | IL287145A (es) |
MA (1) | MA55608A (es) |
MX (1) | MX2021012507A (es) |
SG (1) | SG11202111232RA (es) |
TW (1) | TW202103705A (es) |
WO (1) | WO2020210418A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4048279A1 (en) | 2019-10-21 | 2022-08-31 | Celgene Corporation | Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1. 3-dione |
CA3154890A1 (en) * | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion |
JP2022552884A (ja) * | 2019-10-21 | 2022-12-20 | セルジーン コーポレーション | (s)-2-(2,6-ジオキソピペリジン-3-イル)-4-((2-フルオロ-4-((3-モルホリノアゼチジン-1-イル)メチル)ベンジル)アミノ)イソインドリン-1,3-ジオンを含む医薬組成物およびその使用方法 |
AU2020372334A1 (en) | 2019-10-21 | 2022-05-05 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use |
CN114929686A (zh) | 2019-10-21 | 2022-08-19 | 新基公司 | 包含(s)-2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮及其盐的固体形式,以及含有其的组合物及它们的用途 |
US11666579B2 (en) | 2019-10-21 | 2023-06-06 | Celgene Corporation | Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione |
WO2022212384A1 (en) * | 2021-03-29 | 2022-10-06 | Juno Therapeutics, Inc. | Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphoma |
BR112023019943A2 (pt) * | 2021-04-21 | 2023-11-14 | Bristol Myers Squibb Co | Métodos de tratamento de linfoma de células b usando terapia combinada |
MX2023012294A (es) * | 2021-04-21 | 2023-10-26 | Celgene Corp | Metodos de tratamiento del linfoma no hodgkin mediante el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin- 1-il) metil)benzil)amino)isoindolin-1,3-diona. |
EP4359380A1 (en) | 2021-06-21 | 2024-05-01 | Celgene Corporation | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline-1,3-dione |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3202460T (lt) * | 2010-02-11 | 2019-10-10 | Celgene Corporation | Arilmetoksi izoindolino dariniai ir kompozicijos, apimantys ir jų panaudojimo būdus |
US20140221427A1 (en) * | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
EP2882442B1 (en) * | 2012-08-09 | 2021-06-09 | Celgene Corporation | Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
JP6469077B2 (ja) * | 2013-04-02 | 2019-02-13 | セルジーン コーポレイション | 4−アミノ−2−(2,6−ジオキソ−ピペリジン3−イル)−イソインドリン−1,3−ジオンを使用する中枢神経の癌の治療及び管理のための方法及び組成物 |
PL3214081T3 (pl) * | 2014-10-30 | 2021-04-06 | Kangpu Biopharmaceuticals, Ltd. | Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie |
BR112020000442A2 (pt) * | 2017-07-10 | 2020-07-21 | Celgene Corporation | compostos antiproliferativos e métodos de uso dos mesmos |
FI3784663T3 (fi) * | 2018-04-23 | 2023-10-06 | Celgene Corp | Substituoituja 4-aminoisoindoliini-1,3-dioniyhdisteitä ja niiden käyttö lymfooman hoitamiseksi |
-
2020
- 2020-04-08 AR ARP200101015A patent/AR119715A1/es unknown
- 2020-04-09 BR BR112021020372A patent/BR112021020372A2/pt unknown
- 2020-04-09 TW TW109112033A patent/TW202103705A/zh unknown
- 2020-04-09 CA CA3132538A patent/CA3132538A1/en active Pending
- 2020-04-09 AU AU2020270917A patent/AU2020270917A1/en active Pending
- 2020-04-09 MA MA055608A patent/MA55608A/fr unknown
- 2020-04-09 CN CN202080043197.0A patent/CN114144182B/zh active Active
- 2020-04-09 KR KR1020217036544A patent/KR20210151895A/ko unknown
- 2020-04-09 MX MX2021012507A patent/MX2021012507A/es unknown
- 2020-04-09 SG SG11202111232RA patent/SG11202111232RA/en unknown
- 2020-04-09 EP EP20722180.5A patent/EP3952880A1/en active Pending
- 2020-04-09 WO PCT/US2020/027358 patent/WO2020210418A1/en unknown
- 2020-04-09 US US16/844,407 patent/US11390617B2/en active Active
- 2020-04-09 JP JP2021559978A patent/JP2022527398A/ja active Pending
-
2021
- 2021-10-08 CL CL2021002651A patent/CL2021002651A1/es unknown
- 2021-10-10 IL IL287145A patent/IL287145A/en unknown
-
2022
- 2022-06-24 US US17/848,976 patent/US20220324855A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021020372A2 (pt) | 2021-12-07 |
TW202103705A (zh) | 2021-02-01 |
AR119715A1 (es) | 2022-01-05 |
MA55608A (fr) | 2022-02-16 |
US11390617B2 (en) | 2022-07-19 |
AU2020270917A1 (en) | 2021-11-04 |
IL287145A (en) | 2021-12-01 |
EP3952880A1 (en) | 2022-02-16 |
US20200325129A1 (en) | 2020-10-15 |
CN114144182B (zh) | 2024-05-24 |
US20220324855A1 (en) | 2022-10-13 |
CN114144182A (zh) | 2022-03-04 |
KR20210151895A (ko) | 2021-12-14 |
WO2020210418A1 (en) | 2020-10-15 |
CA3132538A1 (en) | 2020-10-15 |
MX2021012507A (es) | 2022-01-24 |
CL2021002651A1 (es) | 2022-04-29 |
JP2022527398A (ja) | 2022-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287145A (en) | Methods for treating non-Hondkin's lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 , 3-dione | |
ZA202101797B (en) | Hair treatment compositions, methods, and kits for treating hair | |
EP4048668A4 (en) | METHODS OF TREATING HEMATOLOGICAL CANCER AND USE OF COMPANION BIOMARKERS FOR 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL) BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | |
EP3796909A4 (en) | TREATMENT OF MULTIPLE MYELoma AND USE OF BIOMARKERS FOR 4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)-PIPERAZINE -1-YL)-3-FLUOROBENZONITRILE | |
SI3644999T1 (sl) | Sestavki in postopki uporabe 2-(4-klorofenil)-N-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il) metil)-2,2-difluoroacetamida | |
IL290840A (en) | Preparations and methods for altering cd123 | |
IL282006A (en) | Treatment of bone tremor using (R)-2-(4-isopropylphenyl)-N-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide | |
IL284509A (en) | Compounds and methods of use of 2-(4-chlorophenyl)-N-((2-(26-deoxypyricin-3-yl)-1-(oxoisoindolin-5-yl)meranyl)-2,2-difluoroacetamide | |
IL276358A (en) | COMPOUNDS AND METHODS FOR THE TREATMENT OF ADDICTION AND RELATED DISORDERS | |
EP3849478A4 (en) | DEVICE AND METHOD FOR TREATMENT OF WALKING DISORDERS | |
IL284680A (en) | Solid forms including (S) -4-(4-(4 - (((2-(2,6-dioxopyridin-3-YL)-1-oxoisindin-4-YL)oxy)methyl)benzyl)PIPERAZIN-1- YL)-3-Fluorobenzityl and salts thereof, and the overall compositions and methods of using the same | |
EP4054578A4 (en) | COMBINATION THERAPY WITH 2-(4-CHLOROPHENYL)-N-((2-(2,6-DIOXOPIPERIDINE-3-YL)-1-OXOISOINDOLINE-5-YL) METHYL)-2,2-DIFLUOROACETAMIDE | |
EP3863530A4 (en) | SYSTEM, METHOD AND DEVICE FOR THE IMPROVED TREATMENT OF GASTROESOPHAGEAL REFLUX | |
IL288440A (en) | Materials and methods for the treatment of retinopathy | |
IL292266A (en) | Methods for the treatment of hematological malignancy using -(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1.3-dione) | |
EP3740328A4 (en) | MULTI-PURPOSE MACHINE FOR SURFACE TREATMENT AND THE APPROPRIATE PROCESS | |
EP3873498A4 (en) | METHODS AND COMPOSITIONS FOR TREATING HEPATOCELLULAR CARCINOMA USING ANTISENSE NUCLEIC ACIDS | |
EP3939469A4 (en) | HAIR HOLDING TOOL AND HAIR TREATMENT METHOD USING THE SAME | |
SG11201912281PA (en) | 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof | |
IL276437A (en) | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for the treatment of diffuse large B-cell lymphoma | |
IL307942A (en) | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl) methyl)benzyl) amino)isoindoline -1, 3-dione | |
MX2022004687A (es) | Formas solidas que comprenden (s)-2-(2,6-dioxopiperidin-3-il)-4-(( 2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindol in-1,3-diona y sales de las mismas, y composiciones que comprenden la misma y su uso. | |
IL292265A (en) | Methods for treating chronic lymphocytic leukemia using 2-(2,6 deoxypyridin-3yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3- discussion | |
IL284665A (en) | Pharmaceutical compounds consisting of (S)-4- (4- (4- (((2- (2,6-dioxopyridin-3-yl)-1-oxoisoinolin-4-yl)oxy)methyl)benzyl)piperazine-1- YL)-3-fluorobenzonitrile and methods of using the same | |
IL292258A (en) | Pharmaceutical preparations comprising (s)-2-(2,6-deoxypyridin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1 3, discussion and methods of using them |